RBL2 and non-small cell lung carcinoma: In our recent study we found NSCLC cell lines with low RBL2 expression and high expression of AURK pathway genes had heightened sensitivity to AURK pathway inhibitors alone or with paclitaxel (PTX), a standard NSCLC chemotherapy agent.